- Open Access
- Open Peer Review
Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws
Head & Face Medicine volume 8, Article number: 5 (2012)
This literature review aims to evaluate the epidemiologic profile of patients with rheumatoid arthritis (RA) that developed a bisphosphonate-related osteonecrosis that affect the jaws (BRONJ), including demographic aspects, as well as clinical and therapeutic issues. A search of PUBMED/MEDLINE, Scopus, and Cochrane databases from January 2003 to September 2011 was conducted with the objective of identifying publications that contained case reports regarding oral BRONJ in RA patients. Patients with RA who develop oral BRONJ are usually women above 60 years taking steroids and long-term alendronate. Most of them have osteoporosis, and lesions, triggered by dental procedures, are usually detected at stage II in the mandible. Although there is no accepted treatment protocol, these patients seem to have better outcomes with conservative approaches that include antibiotic therapy, chlorhexidine, and drug discontinuation.
Bisphosphonates (BPs) are stable synthetic analogs of inorganic pyrophosphate that suppress osteoclast-mediated bone resorption . In this way, they have been widely used to stabilize bone loss in patients with rheumatoid arthritis (RA), especially those who develop osteoporosis, which is a common feature in this rheumatic disease . However, since 2003, great concern has been generated regarding the side-effects of these drugs through increasing reports, worldwide, of a bisphosphonate-related osteonecrosis that affect the jaws (BRONJ).
There are many hypotheses regarding BRONJ pathogenesis, but none of them is completely accepted. Although there have been reports with no obvious co-morbidity factors [3, 4], it is reasonable to believe that co-factors may play a relevant role in the development of these lesions, especially in patients taking oral BPs. Among these co-factors, RA has been included as a relevant risk factor for BRONJ; however, until now the relationship between these diseases has not been fully explained.
Due to the greater number of patients taking oral BPs for the treatment of RA and osteoporosis, it is very important for risks to be assessed. Thus, the purpose of this extended literature review is to evaluate relevant issues of patients with RA who developed oral BRONJ, including demographic, clinical, and treatment aspects, with the goal of establishing comparative associations with patients without RA who developed oral BRONJ.
We performed a computerized search to identify all papers published in English from January 2003 to September 2011 in PUBMED/MEDLINE, Scopus, and Cochrane databases. Case reports, case series, and retrospective studies were included, while short communications and letters to the Editor were excluded. The studies were approved by the Ethics in Human Research Committee and were in compliance with the ethical principles of the Helsinki Declaration. Literature reviews and systematic reviews also were considered with the objective of identifying cases already reported. The key MeSH (Medical Subject Headings) terms used were: diphosphonates, bisphosphonate, jaw osteonecrosis, rheumatoid arthritis, and rheumatologic.
The primary objective was to identify all articles containing clinical reports with the following inclusion criteria:
Diagnosis of RA and oral BRONJ
Patients with no prior history of radiation to the craniofacial region
At least five areas of the specific demographics were collected, including gender, age, bisphosphonate type and length of exposure, concomitant medications, trigger event, clinical features, staging, lesion site, imaging and histological features, as well as management and outcomes. The stage of the lesions was retrieved directly from the papers or it was defined based on the available clinical data and according to the classification system by Ruggiero et al. .
Papers published in English
All titles and abstracts from the results of the literature search were reviewed by the authors for potential inclusion in our study. We also searched the related links of all relevant papers. Furthermore, all relevant papers were checked to avoid multiple inclusions of the same patients in this study.
The search strategy yielded 1606 titles/abstracts from the databases analyzed. After title, abstract screening, and/or paper analyses, 331 potentially relevant studies were identified and screened for retrieval. Of these, 312 studies were excluded due to non-compliance with the inclusion criteria, one paper was excluded due to duplicity of one patient and, finally, 17 were included in the present review, consisting of 27 patients and 29 BRONJ lesions (Tables 1, 2, 3, and 4).
The patients from this literature review ranged in age from 55 to 79 yr and the mean age was 67 years. Among the 22 patients whose age was reported, 17 (77.3%) were above 60 years old [6, 8, 10–12, 14–16, 18–21], 25 patients reported the gender and only one was male  (Table 1). Furthermore, osteoporosis was the most common co-morbidity observed in this review, being present in 18 patients (66.6%) [4, 9–11, 14–16, 18–21], followed by hypertension (29.6%) [6, 16, 18–20] and diabetes mellitus (14.8%) [8, 15, 20] (Table 1).
Characteristics of bisphosphonate treatment
Among the 24 patients that reported the use of BPs, 22 (91.6%) affirmed to use alendronate [4, 6–9, 11, 12, 15, 16, 18–21], while 2 other patients were using ibandronate  or risedronate  (Table 1). The mean duration of BP therapy was 48 months, ranging from 6 months to 10 years, and most of the patients (73%) were using BPs for 3 or more years [4, 6, 9, 12, 15–17, 19–21] (Table 1).
Most of the oral BRONJ cases in this literature review were triggered by dental surgery procedures (51.7%), such as tooth extraction and dental implants, observed in 13 patients [4, 5, 7–9, 12, 14, 17–20]. Of note, a large proportion of BRONJ lesions appeared spontaneously (41.38%) [9, 10, 12, 13, 15, 19–21] (Table 2).
BRONJ lesions were located most commonly in the lower jaw (72.4%), especially in the posterior area [4, 6, 9, 12–15, 17, 19, 21]. The main signs and symptoms reported in the studies included: bone exposure in 82% of the lesions [4, 6, 7, 9, 11–18, 20, 21], followed by pain (78.5%) [4, 6, 7, 10–14, 16–21], edema (35.7%) [6, 7, 10, 12, 15, 17–19, 21] and purulent discharge (35.7%) [6, 11, 13–15, 17, 19, 21]. Moreover, according to a staging system , 28 lesions were diagnosed at stage II or III, and only one was at stage I (Table 2). Furthermore, most of the patients (62.5%) presented a lytic pattern observed on image exams [4, 12, 16–19, 21], followed by bone sclerosis that was reported in six patients (37.5%) [7, 12, 17, 19, 21].
Regarding the management of the BRONJ lesions, the studies showed the treatment either by conservative therapy alone (48%) [9, 10, 12, 14, 17, 19, 20] or associated with surgical procedures (52%) [4, 6, 7, 12, 13, 15–19, 21]. The treatment only with conservative therapy was associated with the most positive outcomes, including the complete healing of the lesions (33.3%) [9, 12], partial and general positive results (58.3%) [10, 14, 19, 20] and only one patient presented a non-healed lesion (8.33%)  (Table 4).
The association of conservative and surgical therapy showed more diverse results, with complete healing in 3 lesions (25%) [13, 21], partial and general positive results (41.6%) [6, 7, 12, 18, 19] and 4 lesions were classified as non-healed (33.4%) [4, 6, 15, 17] (Table 4).
Until the present moment, there is no randomized, controlled, prospective clinical trial that assessed jaw osteonecrosis (ONJ) risk in patients with rheumatoid arthritis who were using oral BPs. In the absence of this data, the present paper performed a critical literature review to investigate the current status of the epidemiological aspects of patients with rheumatoid arthritis affected by BRONJ.
Considering the prevalence of BRONJ lesions in patients with RA, we considered only the raw number of oral BRONJ reports in RA patients, since the accurate number of non-neoplasic patients treated with oral BPs is unknown; therefore, the determination of the precise prevalence of BRONJ is extremely difficult but is possible to be estimated based on epidemiological studies.
Two reviews published recently, reporting patients that presented BRONJ induced by the use of oral BPs, observed a very low prevalence of these lesions in patients with rheumatic diseases [22, 23]. Other studies reported that the BRONJ prevalence in patients treated with oral BPs, ranges from 0.001% to 0.4% [17, 24–27]. These numbers give the idea that the prevalence of BRONJ lesions in patients with RA is expected to be quite low, however it should be considered that the proportion of patients with rheumatic disease among all the population sampled in these studies is probably reduced as well.
At the same time, it is reasonable to expect an increased tendency in the number of BRONJ lesions in RA patients considering that there is a lack of knowledge about this disease among rheumatologists in many countries and that BPs are among the most frequent prescribed drugs in rheumatologic practice . This is due to the high efficiency of BPs in the prevention and treatment of osteoporosis, which is a common feature in RA .
There is a considerable discussion in the literature whether aging plays a significant role in BRONJ development. Some studies found no statistically significant correlation between aging and BRONJ [30, 31]. Therefore, the advanced age of the patients with BRONJ observed in the studies [6, 8, 10–12, 14–16, 18–21] may reflect nothing less than the increased BPs prescription to older patients compared with younger ones, since osteoporosis and RA are commonly seen in the elderly [29, 32].
On the other hand, other authors include advanced age as a BRONJ co-factor [19, 33, 34], which could be related to the physiological effects of aging, including inflammatory issues , immune dysfunction , reduction of the blood flow and the remodeling ability [37, 38], and increased oxidative stress . In fact, these features are all implicated with BRONJ pathogenesis and could explain why this disease is not reported in young patients, even with other risk factors associated . Paradoxically, BPs have been prescribed for the treatment of steroid-induced osteonecrosis of the joints in pediatric populations .
Controversial aspects have also been discussed regarding gender as a BRONJ co-factor. Some studies found no statistically significant correlation between gender and BRONJ [33, 34]. Therefore, we observed that the large proportion of female patients from the studies [4, 6–11, 13–16, 18–21] can represent only a coincidence, since women take oral BPs more frequently than males, especially because RA and osteoporosis are more common in women .
In spite of that, other authors reported a positive correlation between gender and BRONJ . It has been speculated that estrogen therapy may play a role in this correlation, since hormonal reposition has been associated with an increased risk of BRONJ . The concern is that hormonal replacement therapy is likely to occur in RA, since this disease is often worsened after estrogen delivery . In fact, the association of BPs and estrogen reposition is especially possible in patients with no satisfactory outcomes associated with a single drug therapy or who have very low bone density with multiple risks . Moreover, treatment with estrogen/bisphosphonate conjugate drugs has also been described .
It is not surprising that osteoporosis was the most prevalent co-morbidity observed in the studies [4, 9–11, 14–16, 18–21], since this is a common feature in RA patients for several reasons, including: (a) post-menopausal women represent part of the main risk group for RA and are at risk for accentuated bone loss; (b) steroid therapy is often prescribed for the treatment of RA; (c) physical inactivity is characteristic of RA due to disease activity; and (d) bone loss due to inflammatory disease mechanisms, such as elevated levels of systemic cytokines .
It has been shown that there is a direct relation between BRONJ occurrence and BPs potency [13, 33], which is supported by the high incidence of BRONJ in patients receiving intravenous BPs , as well as by faster lesion onset in these patients . This assumption corroborates with the higher incidence of BRONJ in patients using alendronate, as seen in the studies revised here [4, 6–9, 11, 12, 15, 16, 18–21], since it is the most potent drug among the BPs .
In contrast, Kos and Luczak  found no correlation between the type of BPs and BRONJ incidence, which reinforces the assumption that it can be only a coincidence. In fact, over the last decade, alendronate was among the most used drugs in the USA as first-line therapy for the prevention or treatment of osteoporosis , both in non-neoplasic BRONJ patients without RA [6, 9, 14, 16] and in patients with RA . Furthermore, it is reasonable to understand why ibandronate, a potent nitrogen-containing bisphosphonate (N-BPs)  that is much less prescribed compared with alendronate, is not associated with large-series cases of BRONJ .
It has been discussed that one of the most critical factors for BRONJ is the duration of oral BPs therapy [9, 33]. It is believed that there is an increased incidence of oral BRONJ in patients treated with oral BPs for more than 3 years [5, 9], which is in agreement with the findings of the studies revised here [4, 6, 9, 12, 15–17, 19–21]. In fact, longer-term use of oral BPs may have a dose-equivalence effect, potentially approximating BPs levels in bone thought to be achieved only through high-dose intravenous delivery , and the total dose administered over a long period of time is important for the magnitude of the bone turnover reduction .
An interesting observation is that it has been suggested a trend of early-onset lesions due to steroids therapy . However, this tendency was not confirmed in the patients of the studies revised in this paper, since the mean duration of BP therapy in steroid-treated patients was similar to patients that have not been treated with this drug. Furthermore, some authors reported early-onset lesions in patients with RA and no history of steroids [3, 19].
The literature indicates a strong association of BRONJ with dental surgical procedures in all groups of patients [3, 5, 9]. Although we also observed this tendency in the large number of lesions triggered by teeth extractions and dental implants in the studies that were retrieved [4, 5, 7–9, 12, 14, 17–20], it is relevant to state that spontaneous occurrence of BRONJ lesions was observed in a significant proportion of individuals in several studies [9, 10, 12, 13, 15, 19–21].
Most of the lesions in the studies were diagnosed in lower jaw at stage II or III [4, 6–21] with the most common clinical findings being bone exposure, pain, edema, and purulent discharge. In fact, it also represents the same clinical aspects found in patients with no RA [6, 9, 14, 16]. This evidence brings to light the lack of knowledge and attention about early clinical features that include non-specific signs and symptoms in the oral cavity, including no clinical evidence of bone exposure. The concern is that lesions can progress rapidly, and, in advanced stages, paresthesia, fistula formation, and pathologic fracture can also occur, even in RA patients .
The typical imaging finding in all groups of patients with BRONJ is the association of osteolysis and sclerosis aspects. Within this context, when it is considered that bone sclerosis is often detected in the initial stages of BRONJ , this sign can also be maintained in advanced stages; indeed, we observed in the studies that bone sclerosis was reported in six patients, all classified in advanced stages [7, 12, 17, 19, 21]. Therefore, a careful dental examination could allow an early diagnosis and intervention and assist the patients in responding more promptly to stage-specific treatment regimens for BRONJ.
Regarding the management and outcomes of BRONJ lesions in patients with RA, there is no widely accepted treatment protocol to BRONJ. Some authors believe that surgical procedures are not effective in patients with BRONJ and have led to further bone exposure, worsening of symptoms, and a greater risk of pathologic fracture, indicating conservative approaches as the best choice, including antibiotics, oral rinses with chlorhexidine, and 'drug holidays'. In contrast, other authors believe that surgical procedures may achieve better outcomes in non-neoplasic patients .
In the papers that we revised, the lesions were treated either by conservative therapy (48%) or its association with surgical procedures (52%). Overall, this literature review showed that most of the lesions were treated with conservative approach [9, 10, 12, 14, 17, 19, 20] and were associated with the most positive outcomes including the complete healing of the lesions (33.3%) and no healing in only one patient (8.33%)  (Table 4). However, in other studies [4, 6, 7, 12, 13, 15–19, 21] the association of conservative and surgical therapy showed more diverse outcomes, with complete healing in only three lesions (25%) [13, 21].
In fact, the management of BRONJ lesions is a great challenge, which reinforces the necessity of an adequate oral care through routine dental examinations, education and motivation of the patients to adopt preventive measures in order to maintain a good oral hygiene and .
The main characteristics of BRONJ patients with RA are generally similar to those with no RA. This critical review highlights a serious concern regarding the delayed diagnosis of BRONJ lesions, since most of these patients were diagnosed in stage II/III. It is clear that the rheumatologist needs to be aware of the potential risk of their patients developing BRONJ and must work together with the dentist to prevent and detect the lesions as soon as possible.
NCN is a PhD student from Implantology program at Araraquara School of Dentistry and ASB is a PhD student from Periodontology program at Araraquara School of Dentistry. EMJ and RACM are professors and chairmen of the Department of Diagnosis and Surgery, Division of Periodontology at Araraquara School of Dentistry.
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J: Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000, 88: 2961-2974. 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L.
Breuil V, Euller-Ziegler L: Bisphosphonate therapy in rheumatoid arthritis. Joint Bone Spine. 2006, 73: 349-354. 10.1016/j.jbspin.2005.10.019.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004, 62: 527-534. 10.1016/j.joms.2004.02.004.
Marunick M, Miller R, Gordon S: Adverse oral sequelae to bisphosphonate administration. J Mich Dent Assoc. 2005, 87: 44-49.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B: American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. J Oral Maxillofac Surg. 2009, 67: 2-12.
Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S: Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int. 2007, 18: 1363-1370. 10.1007/s00198-007-0384-2.
Malden NJ, Pai AY: Oral bisphosphonate associated osteonecrosis of the jaws: three case reports. Br Dent J. 2007, 203: 93-97. 10.1038/bdj.2007.636.
Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I: Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab. 2007, 92: 1172-1175.
Marx RE, Cillo JE, Ulloa JJ: Oral bisphosphonates induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007, 65: 2397-2410. 10.1016/j.joms.2007.08.003.
Hamada S: Osteonecrosis of jaw associated with oral application of bisphosphonates. J Oral Maxillofac Surg. 2007, 65: 43-
Barrow SY: Is your knowledge up-to-date?. Int J Dent Hyg. 2010, 8: 319-323. 10.1111/j.1601-5037.2010.00468.x.
Junquera L, Gallego L, Cuesta P, Pelaz A, de Vicente JC: Clinical experiences with bisphosphonate-associated osteonecrosis of the jaws: analysis of 21 cases. Am J Otolaryngol. 2009, 30: 390-395. 10.1016/j.amjoto.2008.07.014.
Mehanna P, Goddard R: Bisphosphonate associated osteonecrosis: an unusual case. Aust Dent J. 2010, 55: 311-313. 10.1111/j.1834-7819.2010.01240.x.
Favia G, Pilolli GP, Maiorano E: Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol. 2009, 36: 2780-2787. 10.3899/jrheum.090455.
Kwon YD, Kim YR, Choi BJ, Lee DW, Kim DY: Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday. Quintessence Int. 2009, 40: 277-278.
Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF: Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 2009, 140: 61-66.
Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D: Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010, 68: 243-253. 10.1016/j.joms.2009.03.050.
Shin EY, Kwon YH, Herr Y, Shin SI, Chung JH: Implant failure associated with oral bisphosphonate-related osteonecrosis of the jaw. J Periodontal Implant Sci. 2010, 40: 90-95. 10.5051/jpis.2010.40.2.90.
Park W, Kim NK, Kim MY, Rhee YM, Kim HJ: Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases. Osteoporos Int. 2010, 21: 527-533. 10.1007/s00198-009-0973-3.
Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P: Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg. 2011, 40: 277-284. 10.1016/j.ijom.2010.11.002.
Conte-Neto N, Bastos AS, Chierici-Marcantonio RA, Marcantonio E: Oral bisphosphonate-related osteonecrosis of the jaws in rheumatoid arthritis patients: a critical discussion and two case reports. Head Face Med. 2011, 27: 1-7.
Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS: Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med. 2008, 121: 475-483.e3. 10.1016/j.amjmed.2008.01.047.
Filleul O, Crompot E, Saussez S: Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010, 136: 1117-1124. 10.1007/s00432-010-0907-7.
Mavrokokki T, Cheng A, Stein B, Goss A: Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007, 65: 415-423. 10.1016/j.joms.2006.10.061.
Felsenberg D, Hoffmeister B, Amling M, Mundlos S, Seibel MJ, Fratzl P: Kiefernekrosen nach hoch dosierter bisphosphonattherapie. Deutsches Arzteblatt. 2006, 103: A3078-A3080.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the american society for bone and mineral research. J Bone Miner Res. 2007, 22: 1479-1491. 10.1359/jbmr.0707onj.
Sambrook P, Olver I, Goss A: Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician. 2006, 35: 801-803.
Yip RML: Bisphosphonates and osteonecrosis of the jaw. Hong Kong Bull Rheum Dis. 2008, 8: 19-25.
Joffe I, Epstein S: Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum. 1991, 20: 256-272. 10.1016/0049-0172(91)90021-Q.
Baqain ZH, Sawair FA, Tamimi Z, Bsoul N, Al Edwan G, Almasad JK: Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl. 2010, 92: 489-494. 10.1308/003588410X12699663903395.
Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG: Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009, 27: 5356-5362. 10.1200/JCO.2009.21.9584.
Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N: Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. Osteoporos Int. 2006, 17: 716-723. 10.1007/s00198-005-0037-2.
Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005, 23: 8580-8587. 10.1200/JCO.2005.02.8670.
Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK: Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol. 2006, 24: 8528-
Schiffrin EJ, Morley JE, Donnet-Hughes A, Guigoz Y: The inflammatory status of the elderly: the intestinal contribution. Mutat Res. 2010, 690: 50-56. 10.1016/j.mrfmmm.2009.07.011.
Johnson TE: Recent results: biomarkers of aging. Exp Gerontol. 2010, 41: 1243-1246.
Misawa Y, Kageyama T, Moriyama K, Kurihara S, Yagasaki H, Deguchi T: Effect of age on alveolar bone turnover adjacent to maxillary molar roots in male rats: a histomorphometric study. Arch Oral Biol. 2007, 52: 44-50. 10.1016/j.archoralbio.2006.06.012.
Semba I, Funakoshi K, Kitano M: Histomorphometric analysis of age changes in the human inferior alveolar artery. Arch Oral Biol. 2001, 46: 13-21. 10.1016/S0003-9969(00)00100-X.
Kulikov VY, Fridman YM, Fomin AN: Role of oxidative stress in mechanisms of premature aging in shift labor workers. Alaska Med. 2007, 49: 81-84.
Maines E, Monti E, Doro F, Morandi G, Cavarzere P, Antoniazzi F: Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw. J Bone Miner Metab. 2011,
Chahine C, Cheung MS, Head TW, Schwartz S, Glorieux FH, Rauch F: Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr. 2008, 153: 719-720. 10.1016/j.jpeds.2008.05.003.
Markenson JA: Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin Arthritis Rheum. 1991, 21: 4-12. 10.1016/0049-0172(91)90046-3.
American Dental Association Council on Scientific Affairs: Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006, 137: 1144-1150.
Barrett JH, Brennan P, Fiddler M, Silman A: Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. Arthritis Rheum. 2000, 43: 1010-1015. 10.1002/1529-0131(200005)43:5<1010::AID-ANR8>3.0.CO;2-O.
Tseng LN, Sheu WH, Ho ES, Lan HH, Hu CC, Kao CH: Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women. Metabolism. 2006, 55: 741-747. 10.1016/j.metabol.2006.01.008.
Morioka M, Kamizono A, Takikawa H, Mori A, Ueno H, Kadowaki S: Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. Bioorg Med Chem. 2010, 18: 1143-1148. 10.1016/j.bmc.2009.12.041.
Marx RE, Sawatari Y, Fortin M, Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005, 63: 1567-1575. 10.1016/j.joms.2005.07.010.
Kos M, Luczak K: Bisphosphonates promote jaw osteonecrosis through facilitating bacterial colonization. Biosci Hypotheses. 2009, 2: 34-36. 10.1016/j.bihy.2008.08.004.
Siris ES, Pasquale MK, Wang Y, Watts NB: Estimating bisphosphonate use and fracture reduction among U.S. women age 45 and older, 2001-2008. J Bone Miner Res. 2011, 23: 3-11.
Chapurlat RD, Delmas PD: Drug insight: bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006, 2: 211-219. 10.1038/ncpendmet0121.
Arce K, Assael LA, Weissman JL, Markiewicz MR: Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009, 67: 75-84.
Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S: Bisphosphonate-related osteonecrosis of the jaw: position paper from the allied task force committee of Japanese society for bone and mineral research, Japan osteoporosis society, Japanese society of periodontology, Japanese society for oral and maxillofacial radiology, and Japanese society of oral and maxillofacial surgeons. J Bone Miner Metab. 2010, 28: 365-383. 10.1007/s00774-010-0162-7.
The authors declare that they have no competing interests.
NCN analyzed the records, reviewed all patients' data. ASB drafted the manuscript and helped in writing the text. RACM and EMJ drafted the manuscript and reviewed it critically. All authors read and approved the final manuscript.
Nicolau Conte-Neto, Alliny Souza Bastos, Rosemary Adriana Chierici Marcantonio and Elcio Marcantonio Junior contributed equally to this work.
About this article
Cite this article
Conte-Neto, N., Bastos, A.S., Marcantonio, R.A.C. et al. Epidemiological aspects of rheumatoid arthritis patients affected by oral bisphosphonate-related osteonecrosis of the jaws. Head Face Med 8, 5 (2012) doi:10.1186/1746-160X-8-5
- Rheumatoid arthritis